Alliance Global Partners analyst James Molloy downgrades Alimera Sciences (NASDAQ:ALIM) from Buy to Neutral and lowers the price target from $11 to $4.5.
Alliance Global Partners Downgrades Alimera Sciences to Neutral, Lowers Price Target to $4.5
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.